<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
</table>
| **NSCL-24, NSCL-I**  
Panel request to review the data for entrectinib as a treatment option for *ROS1* rearrangement positive metastatic non-small cell lung cancer (mNSCLC).  
External request: Submission from Genentech, requesting review of the data supporting the inclusion of entrectinib for the treatment of patients with *NTRK* gene fusion-positive mNSCLC and *ROS1*-positive mNSCLC. | Based upon review of the data in the noted references, the panel consensus supported the addition of entrectinib as a preferred first-line treatment option for *ROS1* rearrangement positive mNSCLC. The panel consensus supported a category 2A recommendation.  
- See Submission for references. | YES | NO | ABSTAIN | ABSENT |
| 26 | 0 | 1 | 2 |
| **NSCL-26, NSCL-I**  
Panel request to review the data for entrectinib as a treatment option for *NTRK* gene fusion positive mNSCLC.  
External request: Submission from Genentech, requesting review of the data supporting the inclusion of entrectinib for the treatment of patients with *NTRK* fusion-positive mNSCLC and *ROS1*-positive mNSCLC. | Based upon review of the data in the noted references, the panel consensus supported the addition of entrectinib as a first-line/subsequent treatment option for *NTRK* gene fusion positive mNSCLC. The panel consensus supported a category 2A recommendation.  
- See Submission for references. | YES | NO | ABSTAIN | ABSENT |
| 26 | 0 | 1 | 2 |